Edition:
United States

Chemed Corp (CHE.N)

CHE.N on New York Stock Exchange

231.61USD
17 Nov 2017
Change (% chg)

$-1.46 (-0.63%)
Prev Close
$233.07
Open
$231.72
Day's High
$233.93
Day's Low
$231.29
Volume
39,219
Avg. Vol
30,764
52-wk High
$235.72
52-wk Low
$145.09

Latest Key Developments (Source: Significant Developments)

Chemed reaches final agreement to end civil litigation & false claims act brought by U.S. DOJ in May 2013​
Tuesday, 31 Oct 2017 11:23am EDT 

Oct 31 (Reuters) - Chemed Corp ::Chemed - Reached final agreement to end civil litigation and false claims act brought by U.S. Department of Justice in May 2013​.Chemed Corp - ‍In connection with settlement, Vitas has also agreed to a corporate integrity agreement with office of inspector general​.Chemed - ‍Total settlement estimated at $85 million pre-tax & compares to $90 million pre-tax ($55.5 million after-tax) of estimated settlement cost recorded in Q2.Chemed Corp - ‍Company will fund the settlement with existing cash balances and its bank credit facility​.  Full Article

Chemed reports Q3 earnings per share $2.13
Thursday, 26 Oct 2017 04:15pm EDT 

Oct 26 (Reuters) - Chemed Corp :Chemed reports third-quarter 2017 results.Sees FY 2017 adjusted earnings per share $8.35 to $8.40 excluding items.Q3 adjusted earnings per share $2.15.Q3 gaap earnings per share $2.13.Q3 earnings per share view $2.01 -- Thomson Reuters I/B/E/S.Chemed Corp - qtrly ‍revenue increased 6.3% to $417 million​.Q3 revenue view $413.8 million -- Thomson Reuters I/B/E/S.Chemed Corp qtrly ‍vitas net patient revenue of $289 million, an increase of 2.2%​.Chemed Corp - ‍roto-rooter is forecasted to achieve full-year 2017 revenue growth of 13% to 14%​.Chemed Corp - ‍adjusted ebitda margin for roto-rooter​ for 2017 is estimated at 22.5%.Chemed Corp - ‍revenue growth for vitas in 2017, prior to medicare cap, is estimated to be in range of 2% to 3%​.Chemed Corp - ‍admissions and average daily census for vitas in 2017 are estimated to expand approximately 2% to 3%​.Chemed Corp - ‍full-year 2017 adjusted ebitda margin for vitas, prior to medicare cap, is estimated to be 15.0% ​.  Full Article

Chemed Corp increases quarterly dividend 7.7 pct
Friday, 4 Aug 2017 12:16pm EDT 

Aug 4 (Reuters) - Chemed Corp ::Chemed Corporation increases quarterly dividend 7.7 pct.Says declared quarterly cash dividend of 28-cents per share .  Full Article

Chemed Corp qtrly ‍adjusted diluted eps $2.15​
Tuesday, 25 Jul 2017 04:59pm EDT 

July 25 (Reuters) - Chemed Corp :Chemed Corp qtrly ‍adjusted diluted EPS $2.15​.Chemed Corp qtrly ‍revenue increased 6.3% to $415 million​.Chemed Corp qtrly earnings per share loss‍ $1.35​.Chemed Corp qtrly ‍net patient revenue of $285 million, an increase of 2.1%​.Chemed Corp - ‍revenue growth for VITAS in 2017 is estimated to be in range of 2% to 3%​.Chemed Corp qtrly ‍net revenue for VITAS was $285 million in Q2 of 2017, which is an increase of 2.1%, when compared to prior-year period​.Chemed Corp sees ‍full-year 2017 adjusted earnings per diluted share in range of $8.10 to $8.20​.Chemed Corp - sees ‍2017 VITAS admissions and average daily census in 2017 estimated to expand approximately 3% to 5%​.Chemed Corp - ‍Roto-Rooter is forecasted to achieve full-year 2017 revenue growth of 12% to 13% in 2017​.Chemed corp - ‍adjusted EBITDA margin for 2017 is estimated in range of 22.0% to 22.5% for Roto-Rooter​.Chemed corp - sees ‍VITAS full-year adjusted EBITDA margin estimated to be 15.0% to 15.5%​.Q2 earnings per share view $1.89, revenue view $407.0 million - Thomson Reuters I/B/E/S.  Full Article

Chemed reports Q1 GAAP earnings per share $1.78
Wednesday, 26 Apr 2017 04:15pm EDT 

April 26 (Reuters) - Chemed Corp :Chemed reports first-quarter 2017 results.Q1 adjusted earnings per share $1.82.Q1 GAAP earnings per share $1.78.Q1 revenue rose 4 percent to $406 million.Says revenue growth for vitas in 2017, prior to medicare cap, is estimated to be in range of 4% to 5%.Sees FY 2017 adjusted earnings per share $7.80 to $8.00 excluding items.Chemed Corp qtrly net patient revenue of $282 million, an increase of 1.7%.Says admissions and average daily census in 2017 are estimated to expand approximately 3% to 4%.Says full-year adjusted ebitda margin, prior to medicare cap, is estimated to be 14.5% to 15.0%.Says currently estimating $3.7 million for medicare cap billing limitations in 2017 calendar year.Says roto-rooter is forecasted to achieve full-year 2017 revenue growth of 3% to 4%.Says adjusted ebitda margin for 2017 is estimated in range of 21.5% to 22.0%.Says full-year 2017 adjusted earnings per diluted share estimated to be in range of $7.80 to $8.00.Q1 earnings per share view $1.79, revenue view $399.8 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $7.90, revenue view $1.64 billion -- Thomson Reuters I/B/E/S.  Full Article

Chemed Corp board authorizes an additional $100 mln for stock repurchase
Monday, 13 Mar 2017 08:30am EDT 

Chemed Corp : Chemed Corp's board of directors authorizes an additional $100 million for stock repurchase .Share repurchases will be funded through a combination of cash generated from operations as well as utilization of its revolving credit facility..  Full Article

CHEMED SETS QUARTERLY DIVIDEND OF $0.26 PER SHARE
Friday, 17 Feb 2017 12:36pm EST 

Chemed Corp :SETS QUARTERLY DIVIDEND OF $0.26 PER SHARE.  Full Article

Chemed Corporation increases quarterly dividend 8.3 pct
Friday, 5 Aug 2016 12:11pm EDT 

Chemed Corp : Chemed Corporation increases quarterly dividend 8.3% .Board of Directors has declared a quarterly cash dividend of 26-cents per share on company's capital stock.  Full Article

Chemed Corp Q2 shr $1.48
Monday, 25 Jul 2016 04:15pm EDT 

Chemed Corp : Sees roto-rooter business FY 2016 revenue up 4 to 5 percent . Says roto-rooter business 2016 adjusted ebitda margin is estimated in range of 20.0% to 21.0% . Quarter 2016 results . Q2 adjusted earnings per share $1.80 . Q2 GAAP earnings per share $1.48 . Sees fy 2016 adjusted earnings per share $7.97 to $8.12 excluding items . Q2 earnings per share view $1.72 -- Thomson Reuters I/B/E/S . Raises full-year earnings guidance . Says full-year 2016 revenue growth for vitas, prior to medicare cap, is estimated to be in range of 1.5% to 3.0% .Qtrly net patient revenue of $279 million, an increase of 0.8%.  Full Article

Chemed Corp reports second-quarter 2016 results
Monday, 25 Jul 2016 04:15pm EDT 

Chemed Corp :Chemed reports second-quarter 2016 results.  Full Article

BRIEF-Chemed reaches final agreement to end civil litigation & false claims act brought by U.S. DOJ in May 2013​

* Chemed - Reached final agreement to end civil litigation and false claims act brought by U.S. Department of Justice in May 2013​